Comparing @entity1 -Derived Xenograft and Computational Response Prediction for Targeted Therapy in XXXX of Early-Stage Large Cell Lung Cancer.

@entity5 @entity1 @entity1149 @entity3866
PURPOSE: Targeted therapy (TT) provides highly effective @entity5 treatment for appropriately selected individuals. A major challenge of TT is to select @entity1 who would benefit most. EXPERIMENTAL DESIGN: The study uses @entity5 material from 25 @entity1 primarily diagnosed with @entity1149 ( @entity1149 ). @entity1 -derived xenografts (PDXs) are treated with cetuximab and @entity3866 . Treatment response is measured by @entity5 shrinkage comparing @entity5 volume at day 25 (V25) with @entity5 volume at baseline (V0). Shrinkage below 40% is considered as treatment response: V25/V0 < 0.4 (<40%). Furthermore, RNA-seq data from each @entity5 sample are used to predict @entity5 response to either treatment using an in silico molecular signaling map (MSM) approach. RESULTS: PDX response was 40% (10/25; 95% CI [21.13%, 61.34%]) under cetuximab and 20% (5/25; 95% CI [6.83%, 40.70%]) under @entity3866 . MSM predicted response was 48% (12/25; 95% CI [27.8%, 68.7%]) under cetuximab and 40% (10/25; 95% CI [21.13%, 61.34%]) under @entity3866 . Agreement between PDX and MSM response prediction is substantial under cetuximab and @entity3866 : 84% (21/25, P = 0.001) and 80% (20/25, P = 0.003). A total of 5 from the 25 @entity1 have been treated with cetuximab showing a clinical response identical to both predictions. CONCLUSIONS: For @entity1149 @entity1 , this proof-of-concept study shows a considerable agreement in response prediction from MSM and PDX approaches, but MSM saves time and laboratory resources. Our result indicates the potential of MSM-based approach for clinical decision making when selecting @entity5 TTs. Clin Cancer Res; 22(9); 2167-76.   2015 AACR.
